An observational study in Endometriosis, sponsored by ZIWIG. Completed at 18 sites in 2 countries. Open to female participants aged 18 Years to 43 Years. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by ZIWIG · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 128 studies in Endometriosis with a site in France — 51 open to participants now, 56 under way, 1 of them phase 3. Endometriosis · France.
Among the 128 studies in Endometriosis with a site in France, this one is the 7th largest by enrollment of the 58 observational ones that give a count, is one of 12 that started in 2021, is one of 58 observational ones, and was the 64th registered.
924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.
Browse Endometriosis studies →51 of the 128 studies in Endometriosis with a site in France are open now. Recruiting first, the newest first:
University Hospital, Limoges · Sites in France
Ages 18–50 · Women only
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+ · Women only
Elsan · Sites in France
Ages 18–45 · Women only
ZIWIG · Sites in France
Ages 18–43 · Women only
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18–40 · Women only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 43 Years · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
128 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 6 · Phase 4 1
First in 1990; this study’s year is marked. 12 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,140 is above the median of 132 across 351 observational studies indexed under Endometriosis.
Median enrollment 91 across the 70 interventional studies, 133 across the 58 observational. Of the 54 that completed or were terminated, 3 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 128 have an industry lead sponsor. The 10 most frequent:
ZIWIG is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
ZIWIG has 6 studies filed under Endometriosis — fewer than ten, so there is no comparison to draw.
21 of the studies in Endometriosis with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973603Institut National de la Santé Et de la Recherche Médicale, FranceExposure to Persistent Organic Pollutants and Severity of Endometriosis in the ComPaRe-Endometriosis Cohort | 2026-12 |
| NCT04704115University Hospital, LilleThe Therapy of Large Endometrioma | 2026-12 |
| NCT06392997ZIWIGEvaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology | 2026-12 |
| NCT07864883University Hospital, Strasbourg, France3D Modeling of Deep Endometriosis From Pelvic MRI | 2026-12-27 |
| NCT04554602Assistance Publique - Hôpitaux de ParisFusion Ultrasound for Diagnosis and Monitoring of Endometriosis Lesions | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 128 studies in Endometriosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ENDOmiARN Salive Test is a multicentre external validation study of a salivary signature of endometriosis carried out in France in Obstetrics and Reproductive Medicine departments, in order to evaluate its performance and discuss its use in clinical practice. The clinical application is to significantly reduce the time to diagnosis and improve the care pathway for endometriosis.
The study population is made up of women aged 18 to 43 years with formally diagnosed endometriosis or suspected endometriosis who are already receiving either medical (MAP) or surgical treatment as part of their routine care.
The patients concerned by the study are managed without any change in the care pathway, nor any change in the therapeutic indications, nor any change in the diagnostic examinations (imaging or biology) required according to the context, which are carried out in accordance with the HAS recommendations.
In this study, the management and follow-up of patients :
Are not modified in comparison with the usual follow-up, except for the performance of :
The study population is made up of women aged 18 to 43 years with a formal diagnosis of endometriosis or suspected endometriosis.
The patients concerned by the study are already receiving either medical (MAP) or surgical care in a department of Obstetrics and Reproductive Medicine.
All these patients already benefit from validation of therapeutic indications in a multidisciplinary consultation meeting (medical-surgical or fertility RCP).
The patients concerned by the study are managed without modification of the care pathway, nor modification of the therapeutic indications, nor modification of the diagnostic examinations (imaging or biology) necessary according to the context, which are carried out according to the recommendations of the HAS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient from one of the 3 study populations:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
At least a 90% Sensitivity (True Positive Rate) of Endometriosis diagnotic confirmation using a miRNA signature
External validation of the salivary signature of endometriosis miRNAs
Time frame: Through the end of study inclusions, an average of 1 year
At least a 90% Specificity (True Negative Rate) of Endometriosis diagnotic confirmation using a miRNA signature
External validation of the salivary signature of endometriosis miRNAs
Time frame: Through the end of study inclusions, an average of 1 year
Ran from Dec 2021 to primary completion in Jan 2023, 12 months.
Of 185 observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ZIWIG